UroGen Pharma Ltd. is a biotech company that focuses on developing and commercializing medical solutions for specialty cancers and urothelial diseases. Its offerings include RTGel, a hydrogel that enhances existing drugs’ therapeutic benefits, and Jelmyto for pyelocalyceal solution. The company's lead product candidate, UGN-102, is currently in Phase III clinical trials for several non-muscle invasive urothelial cancers.